我父亲肺鳞癌的治疗贴(2014年3月1日驾鹤西去）

Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type
NOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9
+ Author Affiliations
! k6 C# }5 J# Y1 b. l7 }4 H
1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan
# h2 ]: {8 j' a) x2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan
8 j+ {. h3 R- p" d: Y5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan
# f4 F' A+ {: a# ?) i6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan
0 Z1 u; |& F& Z& |# d) [0 y7Kinki University School of Medicine, Osaka 589-8511, Japan
# ?) C4 \1 Y. p) {  k8Izumi Municipal Hospital, Osaka 594-0071, Japan
9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan
2 T3 d8 z0 I% i6 tCorrespondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp
  ?" b! M% H* a" i+ \& H9 CAbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type.
1 K3 S; T7 f1 d2 r/ E8 J8 ?& A
$ t$ ~7 q1 M8 h1 u" d

S-1 monotherapy for previously treated non-small cell lung cancer: A retrospective analysis by age and histopathological type
; o( X, x! K) r; A" z) I
0 u( @/ `& m. I$ u, Z" n! ~, AAuthors: Yuki Tomita, Tetsuya Oguri, Osamu Takakuwa, Makoto Nakao, Eiji Kunii, Takehiro  Uemura, Hiroaki Ozasa, Mikinori Miyazaki, Ken Maeno, Shigeki Sato
, K: t3 h4 W' m3 T! v
9 j; h) d9 ~/ Y. cAffiliations: Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601, Japan  
' o) s; _; Y& _$ n$ _: z3 v
Published online on: Thursday, December 1, 2011

Doi: 10.3892/ol.2011.507

Pages: 405-410
5 X( D( W0 O, f/ z5 W$ }- _
9 w6 i+ O0 y, R& p8 S* qAbstract:
8 E& w1 N/ f6 K- H) RS-1, an oral fluoropyrimidine derivative, has been approved for the treatment of non-small cell lung cancer (NSCLC) in Japan. In the present study, the efficacy and safety of S-1 monotherapy for elderly patients with previously treated NSCLC were retrospectively evaluated, and the efficacy of S-1 monotherapy was compared by histopathological type. This retrospective study included 54 patients with advanced or recurrent NSCLC who had received S-1 monotherapy following the failure of previous chemotherapy regimens at our institutes. Patient outcomes were compared based on their age and histopathological type. S-1 was administered orally, twice daily, while the duration and interval were modified according to the medical condition of each patient. The default delivery schedule, the mean number of S-1 cycles, did not differ significantly between the two age groups (<70 and ≥70 years). The rate of therapy discontinuation, schedule modification or dose reduction due to intolerable toxicities or patient refusal was relatively frequent in the older group (40.7 and 55.6% for ages <70 and ≥70 years, respectively; p=0.414), and the incidence of grade 3 anemia was relatively high in the older group (3.7 and 18.5%, respectively; p=0.192). The response rates (13.0 and 4.8%, respectively; p=0.609) and disease control rates (39.1 and 33.3%, respectively; p=0.761) did not differ significantly between the two age groups. According to histopathological type, the disease control rate was significantly higher in adenocarcinoma (57.9%) compared to non-adenocarcinoma (20.0%, p=0.013). Thus, S-1 monotherapy may be equally effective and tolerated in patients <70 years and those ≥70 years. Additionally, adenocarcinoma may have a higher disease control rate than non-adenocarcinoma.

% k) S6 z9 T5 h# j

Thymidylate synthase (TS) gene expression in primary lung cancer patients: a large-scale study in Japanese population
5 P; Q- j1 p# I% g) ]5 MF. Tanaka1,*, H. Wada2, Y. Fukui3 and M. Fukushima3
, J: o: ^' r( [% [# \7 b0 \" B6 A% V+ Author Affiliations
; `: F  E; \* P7 i1Second Department of Surgery, University of Environmental and Occupational Health, Kitakakyushu
! @$ W; C9 \; ^; X/ z2Department of Thoracic Surgery, Kyoto University, Kyoto
3Tokushima Research Center, Taiho Pharmaceutical Co. Ltd, Tokushima, Japan
5 |* D) ~$ B& v& i&#8629;*Correspondence to: Dr F. Tanaka, Second Department of Surgery, University of Environmental and Occupational Health, 1-1 Isegaoka, Yahata-nishi, Kitakakyushu, 807-8555, Japan. Tel: +81-93-891-7442; Fax: +81-93-692-4004; E-mail: ftanaka@med.uoeh-u.ac.jp
/ e$ Q7 h3 j, @7 Z$ oReceived September 3, 2010.
Revision received November 11, 2010.
2 ^1 I) D" L' T7 m: yAccepted November 17, 2010.
Abstract
$ s5 g7 \; c3 P3 \; q! x) \Background: Previous small-sized studies showed lower thymidylate synthase (TS) expression in adenocarcinoma of the lung, which may explain higher antitumor activity of TS-inhibiting agents such as pemetrexed.
Patients and methods: To quantitatively measure TS gene expression in a large-scale Japanese population (n = 2621) with primary lung cancer, laser-captured microdissected sections were cut from primary tumors, surrounding normal lung tissues and involved nodes.
Results: TS gene expression level in primary tumor was significantly higher than that in normal lung tissue (mean TS/β-actin, 3.4 and 1.0, respectively; P < 0.01), and TS gene expression level was further higher in involved node (mean TS/β-actin, 7.7; P < 0.01). Analyses of TS gene expression levels in primary tumor according to histologic cell type revealed that small-cell carcinoma showed highest TS expression (mean TS/β-actin, 13.8) and that squamous cell carcinoma showed higher TS expression as compared with adenocarcinoma (mean TS/β-actin, 4.3 and 2.3, respectively; P < 0.01); TS gene expression was significantly increased along with a decrease in the grade of tumor cell differentiation. There was no significant difference in TS gene expression according to any other patient characteristics including tumor progression.
7 |. z/ N7 T1 DConclusion: Lower TS expression in adenocarcinoma of the lung was confirmed in a large-scale study.

一直关注老马的帖子，前方的指明灯。祝福你爸好疗效

一直得到老马帮助，祝福老马爸爸

26日吃了12片地米（0.75mg一片），27日吃了22片地米（0.75mg 一片），28日吃了12片地米（0.75mg一片），都分二次吃。
2 ~: Q- }0 A, H1 t) N8 _. _今天为止没有任何反应，每天吃VC,VB2，还有漱口水，就怕口腔溃疡。

副作用如何，单药反应很小吧？
/ x9 F4 w, R4 K& I

LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy
+ y: m1 `3 w# ~http://clinicaltrials.gov/ct2/show/NCT01523587

( m9 X* X* r- @& v( F  f, u! I2 ^BIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC
7 a7 o- a+ v' V/ I5 f9 N$ ~http://clinicaltrials.gov/ct2/show/NCT01156545

! ]% P6 v! F/ k1 ]% U
从4月24日开始到4月28日，打了5天的舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。
至今为止，未出现化疗副作用。

老马 发表于 2012-4-29 20:53

                               
登录/注册后可看大图

从4月24日开始到4月28日，打了5天的打了5天舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。
至今为止，未出 ...

没有副作用是第一追求，效果显著是第二追求。
不错。